Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1/2 1Phase 1 1

Status

Completed 3Terminated 2No longer available 1

Sponsor Class

INDUSTRY 3

Study Type

Interventional 3

Sponsor

Cancer Type

Lymphoid 10Sarcoma 6Thoracic 3Other solid neoplasm 3Gastrointestinal 2Other hematologic neoplasm 1Myeloid 1Genitourinary 1CNS 1

Conditions

Mesothelioma 3Sarcoma, Synovial 2Lymphoma, Non-Hodgkin 2Lymphoma, Large B-Cell, Diffuse 2Lymphoma, Follicular 2Sarcoma 1Rhabdoid Tumor 1Hematologic Neoplasms 1

Interventions

Cisplatin 81Gemcitabine 58Carboplatin 57Irinotecan 56Paclitaxel 53Pemetrexed 47Docetaxel 39Nivolumab 33Fluorouracil 30Bevacizumab 27pembrolizumab 25Cyclophosphamide 24Capecitabine 24Oxaliplatin 22Leucovorin 21Topotecan 19durvalumab 17Erlotinib Hydrochloride 17Sorafenib 16Everolimus 16Etoposide 16Bortezomib 16Ipilimumab 15Injections 15Sunitinib 14Filgrastim 14Early Intervention, Educational 14atezolizumab 13alvocidib 13Sirolimus 13

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Completed × tazemetostat × Other solid neoplasm × Clear all
NCT02875548 2025-11-04

TRuST

Ipsen

Phase 1/2 Completed
58 enrolled
LymphoidOther solid neoplasmSarcomaThoracic

Lymphoma, Follicular, Lymphoma, Non-Hodgkin, Mesothelioma, Sarcoma, Synovial, Lymphoma, Large B-Cell, Diffuse

NCT04537715 2025-02-19

Effects of Itraconazole and Rifampin on the Blood Tazemetostat Levels

Ipsen

Phase 1 Completed
42 enrolled 39 charts
LymphoidOther hematologic neoplasmOther solid neoplasmSarcomaThoracic

Lymphoma, Follicular, Lymphoma, Non-Hodgkin, Mesothelioma, Sarcoma, Sarcoma, Synovial, Lymphoma, Large B-Cell, Diffuse, Rhabdoid Tumor, Hematologic Neoplasms

NCT02860286 2021-04-09

Study of the EZH2 Inhibitor Tazemetostat in Malignant Mesothelioma

Epizyme, Inc.

Phase 2 Completed
74 enrolled 23 charts
Other solid neoplasmThoracic

Mesothelioma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡